Allylestrenol

Allylestrenol

Systematic (IUPAC) name
(17β)-17-(prop-2-en-1-yl)estr-4-en-17-ol
Clinical data
Pregnancy cat.	Used in threatened miscarriage and RPL
Legal status	?
Identifiers
CAS number	432-60-0 Y
ATC code	G03DC01
PubChem	CID 235905
DrugBank	DB01431
ChemSpider	205855 Y
UNII	I47VB5DZ8O Y
KEGG	D01374 Y
ChEMBL	CHEMBL1445549 N
Synonyms	17α-Allylestr-4-en-17β-ol
Chemical data
Formula	C21H32O
Mol. mass	300.48 g/mol
SMILES	eMolecules & PubChem
InChI InChI=1S/C21H32O/c1-3-12-21(22)14-11-19-18-9-8-15-6-4-5-7-16(15)17(18)10-13-20(19,21)2/h3,6,16-19,22H,1,4-5,7-14H2,2H3/t16-,17+,18+,19-,20-,21-/m0/s1 Y Key:ATXHVCQZZJYMCF-XUDSTZEESA-N Y
N(what is this?)  (verify)

Allylestrenol (BAN/INN), also known as allyloestrenol and allyl estrenol, is a synthetic progestogen used to prevent threatened miscarriage, recurrent pregnancy loss and premature labor.^[1][2] In men, it has also been studied as a treatment for benign prostatic hyperplasia, with encouraging results.^[3][4]

Allylestrenol is sold under several trade names, including Gestin, Turinal, Gestanin, Gestanol or Gestanon, Maintaine, Orageston, and Profar. It is currently not marketed in the United States, United Kingdom, or Canada, but as of 2011^[update], is extensively used in Japan, Russia, India, and much of Southeast Asia.^[1]

References

1. ^ ^{a b} Sweetman, Sean C., ed (2009). "Sex hormones and their modulators". Martindale: the complete drug reference (36th ed.). London: Pharmaceutical Press. p. 2082. ISBN 978-0-85369-840-1. 
2. ^ Cortés-Prieto J, Bosch AO, Rocha JA (1980). "Allylestrenol: three years of experience with Gestanon in threatened abortion and premature labor". Clinical Therapeutics 3 (3): 200–8. PMID 7459930. 
3. ^ Fukuoka H, Ishibashi Y, Shiba T, Tuchiya F, Sakanishi S (July 1993). "[Clinical study of allylestrenol (Perselin) on patients with prostatic hypertrophy]" (in Japanese). Hinyokika Kiyo. Acta Urologica Japonica 39 (7): 679–83. PMID 7689782. 
4. ^ Noguchi K, Takeda M, Hosaka M, Kubota Y (May 2002). "[Clinical effects of allylestrenol on patients with benign prostatic hyperplasia (BPH) evaluated with criteria for treatment efficacy in BPH]" (in Japanese). Hinyokika Kiyo. Acta Urologica Japonica 48 (5): 269–73. PMID 12094708. 

External links

• "AUA 2007 - Prostate Cancer Basic Research (II)" - Uro Today

Antiprogestin/
SPRM

antagonist: Mifepristone

Asoprisnil • CDB-4124  • Ulipristal acetate

Estrogens

Agonist	Steroidal Diosgenin • Estradiol (Ethinylestradiol#/Mestranol • Estradiol 17 beta-cypionate# • Polyestradiol phosphate) • Estrone (Estrone sulfate) • Estriol • Promestriene • Equilenin • Equilin Nonsteroidal Chlorotrianisene • Dienestrol • Fosfestrol • Diethylstilbestrol • Zeranol
Antiestrogen/ SERM	Afimoxifene • Arzoxifene • Bazedoxifene • Cyclofenil • Lasofoxifene • Ormeloxifene • Raloxifene • Tamoxifen • Toremifene Clomifene# • Mepitiostane • Nafoxidine pure antagonist: Fulvestrant
Aromatase inhibitors	nonselective: Aminoglutethimide • Testolactone selective: Anastrozole • Atamestane • Exemestane • Fadrozole • Formestane • Letrozole • Vorozole

^#WHO-EM. ^‡Withdrawn from market. Clinical trials: ^†Phase III. ^§Never to phase III

M: ♀ FRS anat/phys/devp noco/cong/npls, sysi/epon proc/asst, drug (G1/G2B/G3CD)